Nxxi
- Creatore Discussione Flydixie
- Data di inizio
kingalbert
No Pain No Gain
- Registrato
- 30/8/00
- Messaggi
- 1.407
- Punti reazioni
- 70
magari fosse calma piatta.
Onestamente non capisco. A 2.20 gli alzano il target price a $ 3.30 e questa sprofonda a 1.97.... Mah.... se qualcuno mi spiega....
Grazie
Onestamente non capisco. A 2.20 gli alzano il target price a $ 3.30 e questa sprofonda a 1.97.... Mah.... se qualcuno mi spiega....
Grazie
kingalbert
No Pain No Gain
- Registrato
- 30/8/00
- Messaggi
- 1.407
- Punti reazioni
- 70
Se guardi il grafico intraday in candlestik c'e' un bell'HAMMER in chiusura che lascia sperare qualcosa di veramente buono per domani.
Ci sono dei report su questo titolo che dicono che sul lungo periodo puo' tranquillamente arrivare a 50.
il buon Osinod in qualche post fa aveva azzardato un 100$ ma mi sembra un tantino eccessivo a meno che qualche big farmaceutico non ci metta le mani...
Ci sono dei report su questo titolo che dicono che sul lungo periodo puo' tranquillamente arrivare a 50.
il buon Osinod in qualche post fa aveva azzardato un 100$ ma mi sembra un tantino eccessivo a meno che qualche big farmaceutico non ci metta le mani...
SE ARRIVA A 4 MI VENDO PURE MIA MADRE....kingalbert ha scritto:Se guardi il grafico intraday in candlestik c'e' un bell'HAMMER in chiusura che lascia sperare qualcosa di veramente buono per domani.
Ci sono dei report su questo titolo che dicono che sul lungo periodo puo' tranquillamente arrivare a 50.
il buon Osinod in qualche post fa aveva azzardato un 100$ ma mi sembra un tantino eccessivo a meno che qualche big farmaceutico non ci metta le mani...
Tablas
Nuovo Utente
- Registrato
- 15/4/04
- Messaggi
- 2.453
- Punti reazioni
- 160
Si,probabilmente anche a 150$ dopo aver fatto un paio di split.
Cerchiamo di rimanere nella realtà,sono lungo sul titolo per le potenzialità ma ne deve macinare di utili prima di salire e per ora è tutto da dimostrare nelle prossime trimestrali che Wall Mart e compagnia bella stiano vendendo il loro prodotto.
Cerchiamo di rimanere nella realtà,sono lungo sul titolo per le potenzialità ma ne deve macinare di utili prima di salire e per ora è tutto da dimostrare nelle prossime trimestrali che Wall Mart e compagnia bella stiano vendendo il loro prodotto.
kingalbert
No Pain No Gain
- Registrato
- 30/8/00
- Messaggi
- 1.407
- Punti reazioni
- 70
ORLANDO, FL -- (MARKET WIRE) -- 06/14/2006 -- RedChip Independent, a division of RedChip Companies, today announced research coverage on Nutrition 21 Inc. (NASDAQ: NXXI). RedChip initiated coverage of Nutrition 21 Inc. with a "Strong Buy" rating and a 12 month price target of $3.64.
RedChip Research Analyst Leslie Richardson, CFA Level III Candidate, wrote in the report:
NXXI has recently redefined its strategy from being an ingredient supplier of chromium picolinate to becoming a consumer health product company targeting a potential $4.2 billion market. Moreover, NXXI is creating a new category in nutritional supplements for insulin management similar to the way calcium is positioned for bone health. The Company has two branded products that it sells directly to the consumer, Chromax® chromium picolinate and Diochrome® chromium picolinate and biotin, and one generic for chromium picolinate.
We are placing a target price of $3.64 on NXXI. Our valuation is derived from a P/S of 6x, fiscal 2007 revenues of $27 million and 45 million shares outstanding. At the current price of $1.88, we feel NXXI offers an excellent investment value. The Company is in the early stage of implementing its strategy of creating a new supplement category and being the brand leader. The Company's strong growth is based on the relationships it has built with medical professional concerned with the prevalence of diabetes and other insulin health related problems as well as key retailers. It is also aggressively getting the message out to the American consumer about the health benefits of chromium picolinate supplements in maintaining insulin health.
Highlighted Links
RedChip Companies, Inc.
Nutrition 21 Inc.
To receive a complimentary copy of the RedChip Independent research for NXXI, please visit: http://www.redchip.com/subscriber.asp?page=requestNXXI.
About RedChip Independent™
RedChip Independent Research, a division of RedChip Companies Inc., writes fundamental research on small-cap companies. RedChip's success has been documented in Forbes, Barron's and the Wall Street Journal. Dedicated to "discovering tomorrow's blue chips today™," RedChip's analysts seek out undiscovered, emerging growth companies. For more information, or to subscribe to RedChip research visit www.redchip.com/independent.asp.
Disclosure:
The analysts contributing to this NXXI RedChip report do not hold any shares of NXXI. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. RedChip certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the NXXI RedChip report. Additional information on the securities mentioned in this report is available upon request. This NXXI RedChip report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. As such, the NXXI RedChip report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed herein are subject to change.
RedChip Research Analyst Leslie Richardson, CFA Level III Candidate, wrote in the report:
NXXI has recently redefined its strategy from being an ingredient supplier of chromium picolinate to becoming a consumer health product company targeting a potential $4.2 billion market. Moreover, NXXI is creating a new category in nutritional supplements for insulin management similar to the way calcium is positioned for bone health. The Company has two branded products that it sells directly to the consumer, Chromax® chromium picolinate and Diochrome® chromium picolinate and biotin, and one generic for chromium picolinate.
We are placing a target price of $3.64 on NXXI. Our valuation is derived from a P/S of 6x, fiscal 2007 revenues of $27 million and 45 million shares outstanding. At the current price of $1.88, we feel NXXI offers an excellent investment value. The Company is in the early stage of implementing its strategy of creating a new supplement category and being the brand leader. The Company's strong growth is based on the relationships it has built with medical professional concerned with the prevalence of diabetes and other insulin health related problems as well as key retailers. It is also aggressively getting the message out to the American consumer about the health benefits of chromium picolinate supplements in maintaining insulin health.
Highlighted Links
RedChip Companies, Inc.
Nutrition 21 Inc.
To receive a complimentary copy of the RedChip Independent research for NXXI, please visit: http://www.redchip.com/subscriber.asp?page=requestNXXI.
About RedChip Independent™
RedChip Independent Research, a division of RedChip Companies Inc., writes fundamental research on small-cap companies. RedChip's success has been documented in Forbes, Barron's and the Wall Street Journal. Dedicated to "discovering tomorrow's blue chips today™," RedChip's analysts seek out undiscovered, emerging growth companies. For more information, or to subscribe to RedChip research visit www.redchip.com/independent.asp.
Disclosure:
The analysts contributing to this NXXI RedChip report do not hold any shares of NXXI. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. RedChip certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the NXXI RedChip report. Additional information on the securities mentioned in this report is available upon request. This NXXI RedChip report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. As such, the NXXI RedChip report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed herein are subject to change.
kingalbert
No Pain No Gain
- Registrato
- 30/8/00
- Messaggi
- 1.407
- Punti reazioni
- 70
Un altra società da il giudizio strong buy. Adesso sono 2 su 2.
TP ancora raised. sperem nel botto!
TP ancora raised. sperem nel botto!
Tablas
Nuovo Utente
- Registrato
- 15/4/04
- Messaggi
- 2.453
- Punti reazioni
- 160
PURCHASE, N.Y.--(BUSINESS WIRE)--May 15, 2006--Nutrition 21, Inc. (NASDAQ: NXXI - News), the leading developer and marketer of chromium-based nutritional supplements, today reported financial results for the third quarter ended March 31, 2006.
Presumibilmente sarà intorno al nostro Ferragosto,sperando che non ci facciano un "gavettone" scherzoso.
Comunque i benefici si dovrebbero vedere nel secondo semestre.
Presumibilmente sarà intorno al nostro Ferragosto,sperando che non ci facciano un "gavettone" scherzoso.
Comunque i benefici si dovrebbero vedere nel secondo semestre.
benefici...Tablas ha scritto:PURCHASE, N.Y.--(BUSINESS WIRE)--May 15, 2006--Nutrition 21, Inc. (NASDAQ: NXXI - News), the leading developer and marketer of chromium-based nutritional supplements, today reported financial results for the third quarter ended March 31, 2006.
Presumibilmente sarà intorno al nostro Ferragosto,sperando che non ci facciano un "gavettone" scherzoso.
Comunque i benefici si dovrebbero vedere nel secondo semestre.
kingalbert
No Pain No Gain
- Registrato
- 30/8/00
- Messaggi
- 1.407
- Punti reazioni
- 70
infatti, non si capisce qualcuno ha qualche news?
priz71
the other side of...
- Registrato
- 19/7/03
- Messaggi
- 2.084
- Punti reazioni
- 115
nessuna news,boh....io sono uscito dal titolo........
-o qualcuno sa qualcosa che noi non sappiamo e vende prima che esca la news(gia' visto altre volte)
-oppure la fanno scendere per accumulare a prezzi bassi e poi come al solito uscira' una buona news che fara' risalire il titolo.....
se entrate mettete uno stop adeguato,non si sa mai......
-o qualcuno sa qualcosa che noi non sappiamo e vende prima che esca la news(gia' visto altre volte)
-oppure la fanno scendere per accumulare a prezzi bassi e poi come al solito uscira' una buona news che fara' risalire il titolo.....
se entrate mettete uno stop adeguato,non si sa mai......
kingalbert
No Pain No Gain
- Registrato
- 30/8/00
- Messaggi
- 1.407
- Punti reazioni
- 70
July 06, 2006 12:36:00 PM ETNutrition 21 Joins New Russell Microcap
Nutrition 21, Inc., NXXI announced today that it has been added to the Russell Microcap(TM) Index as of June 30, 2006 when Russell Investment Group reconstituted its family of U.S. Indexes
http://news.moneycentral.msn.com/ticker/article.asp?Feed=BW&Date=20060706&ID=5848077&Symbol=US:NXXI
Nutrition 21, Inc., NXXI announced today that it has been added to the Russell Microcap(TM) Index as of June 30, 2006 when Russell Investment Group reconstituted its family of U.S. Indexes
http://news.moneycentral.msn.com/ticker/article.asp?Feed=BW&Date=20060706&ID=5848077&Symbol=US:NXXI
